May 30th is the World Multiple Sclerosis (MS) Day, which was initiated by International Multiple Sclerosis Alliance in 2009, aiming to arouse the people’s awareness in caring the MS patients, and facilitating the research progress of this disease. The 2021 World MS Day theme is ‘connections’. MS Connections is all about building community connection, self-connection and connections to quality care. At this special day, InnoCare would like to call for caring each MS patient and providing them more support.
MS is an autoimmune, inflammatory disease of the central nervous system. The immune system destroys myelin surrounding nerves disrupting the normal functioning of the brain, optic nerves, and spinal cord through inflammation and tissue loss. It can cause muscle weakness, fatigue, and visual problems, and ultimately lead to disability. It most often appears when people are between 20 to 40 years old and it is the most common cause of non-traumatic neurological disability in young adults.
According to the Multiple Sclerosis International Federation (MSIF), more than 2.8 million people around the world are affected by MS today.
BTK, a key kinase in the B cell receptor signaling pathway, plays important roles in the development and function of B cells, macrophages, and microglia, which are involved in the immunopathological characteristics of MS. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS.
BTK inhibitor orelabrutinib has demonstrated sustained anti-inflammatory activity and safety profile, plus recent finding that orelabrutinib does have a good level of Brain Blood Barrier (BBB) Penetration capability. Currently, the phase II clinical study of orelabrutinib for the treatment of MS is carried out in the United States, Europe and China.
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.